Cullinan Therapeutics Hosts Virtual Event to Discuss REZILIENT3 Trial Results
News related to:Cullinan Therapeutics, Inc · 1 min read
CAMBRIDGE, Mass., Sept. 14, 2026 /CourierPR/ -- Cullinan Therapeutics, a clinical-stage biopharmaceutical company, is set to host a virtual event for analysts and institutional investors today to discuss the latest findings from its Phase 3 REZILIENT3 trial. The trial, which combines zipalertinib with chemotherapy, was presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer.
The virtual event, scheduled for 8:00 a.m. ET, will feature presentations from Cullinan Therapeutics’ CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, MD, MBA. Attendees will have the opportunity to hear about the interim analysis results from the Phase 3 REZILIENT3 trial, which was showcased in a Presidential Symposium at the IASLC conference.
Cullinan Therapeutics specializes in developing potential first- or best-in-class, disease-modifying T cell engagers for both autoimmune diseases and cancer. The company’s pipeline includes a rigorous scientific approach and purposeful innovation, aiming to deliver new standards of care for patients.
The REZILIENT3 trial is a significant milestone for Cullinan Therapeutics, as it evaluates the efficacy and safety of zipalertinib in combination with chemotherapy. The interim analysis results will provide valuable insights into the potential of this treatment for patients with lung cancer.
Cullinan Therapeutics continues to advance its mission to deliver new standards of care for patients, leveraging its expertise in T cell engagers. The company’s commitment to innovation and patient care is evident in its ongoing clinical trials and strategic partnerships.
The virtual event is expected to attract a wide range of stakeholders, including analysts, investors, and healthcare professionals, who are interested in the latest developments in lung cancer treatment. The results from the REZILIENT3 trial could have a significant impact on the future of cancer therapy, potentially offering new hope to patients and their families.